Romidepsin and Afatinib Abrogate Jak –Signal Transducer and Activator of Transcription Signaling and Elicit Synergistic Antitumor Effects in Cutaneous T-Cell Lymphoma

In this study, we demonstrate that the combination of romidepsin, a selective class I histone deacetylase inhibitor, with afatinib, an EGFR family inhibitor, induces strongly synergistic antitumor effects in cutaneous T-cell lymphoma models in  vitro and in vivo through abrogation of Jak–signal transducer and activator of transcription signaling.

Source: Journal of Investigative Dermatology - January 12, 2024 Category: Dermatology Authors: Bobby B. Shih, Cindy Ma, Jose R. Cortes, Clara Reglero, Hannah Miller, S. Aidan Quinn, Robert Albero, Anouchka P. Laurent, Adam Mackey, Adolfo A. Ferrando, Larisa Geskin, Teresa Palomero Tags: Original Article Source Type: research